PDE2A: A New Biomarker for Cancer Prognosis and Immunotherapy
Author Information
Author(s): Yu Zhen, Song Yawen, Wang Jin, Wu Yujing, Wang Hefang, Liu Shuye, Zhu Yu
Primary Institution: Nankai University Affinity the Third Central Hospital, Tianjin Third Central Hospital, Tianjin, China
Hypothesis
What is the role of PDE2A expression in various human cancers and its potential as a prognostic marker and immunotherapy target?
Conclusion
PDE2A expression is significantly reduced in many cancers and is associated with prognosis, suggesting its potential as a biomarker and target for immunotherapy.
Supporting Evidence
- PDE2A expression was significantly reduced in the majority of cancer types compared to normal tissues.
- Cox regression analyses indicated that PDE2A can act as an independent prognostic factor for stomach adenocarcinoma, ovarian serous cystadenocarcinoma, and liver hepatocellular carcinoma.
- Significant associations were observed between PDE2A expression and tumor mutation burden as well as microsatellite instability.
- Single cell sequencing revealed PDE2A's crucial role in regulating differentiation and angiogenesis of cancer cells.
Takeaway
PDE2A is a protein that helps us understand how different cancers grow and respond to treatments, and it might help doctors decide the best way to treat cancer patients.
Methodology
The study used bioinformatics tools to analyze PDE2A expression across various cancer types, correlating it with clinical features, prognosis, and drug sensitivity.
Potential Biases
Potential systematic biases from using multiple public datasets.
Limitations
The analysis relied on publicly available datasets, which may introduce biases, and the sample size for some analyses was relatively small.
Statistical Information
P-Value
4.1e-05
Confidence Interval
95%CI: 1.403-2.906
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website